Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Children’s Motrin lawsuit

This article was originally published in The Tan Sheet

Executive Summary

McNeil Consumer & Specialty Pharmaceuticals is "aware of the report of a seven-year-old girl who has been diagnosed with Stevens-Johnson syndrome, allegedly associated with the use of Children's Motrin," the Johnson & Johnson subsidiary said, responding to a lawsuit filed in Los Angeles Superior Court Dec. 28. The firm said it is "investigating the situation." Seven-year-old Sabrina Brierton Johnson is suing J&J, McNeil, McKesson Corp., Save-On Drug Stores, Cardinal Health and Ralph's Grocery for selling the ibuprofen oral suspension knowing an allergic reaction to the drug could trigger the skin disease Stevens-Johnson syndrome, which in turn may cause blindness. Timing of the suit comes amidst increasing concerns about drug safety, and closely follows the addition of a black box warning mentioning risk of skin diseases, including Stevens-Johnson syndrome, to Pfizer's COX-2 inhibitor Bextra...

You may also be interested in...



Children’s Motrin Suit Seeks Compensation, New Label For Ibuprofen Product

A lawsuit that alleges Children's Motrin with ibuprofen caused a girl's blindness wants McNeil Consumer & Specialty Pharmaceuticals to clearly list all potential serious adverse reactions on the product's label and compensate the child

Takeda, Astellas Found New JV To Support Japanese Bioventures

Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.

Could Eledon’s Anti-CD40L Change Transplant Medicine?

Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation. 

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097678

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel